about
Defining the intensity of conditioning regimens: working definitionsHematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCTNonmyeloablative allogeneic hematopoietic cell transplantationLong-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.Costs of second allogeneic hematopoietic cell transplantation.Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trialDonor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose.Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.Pilot study of a (213)bismuth-labeled anti-CD45 mAb as a novel nonmyeloablative conditioning for DLA-haploidentical littermate hematopoietic transplantation.Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs.Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantationLong-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis.Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trialDonor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation.Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimensOptimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil.Cord-Blood Transplantation in Patients with Minimal Residual DiseaseReagents for astatination of biomolecules. 4. Comparison of maleimido-closo-decaborate(2-) and meta-[(211)At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [(211)At]astatine.Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma: indications and outcomes.Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome.Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation.Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age.Recipient pretransplant inosine monophosphate dehydrogenase activity in nonmyeloablative hematopoietic cell transplantationGraft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas.Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Reduced mortality after allogeneic hematopoietic-cell transplantation.Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of ageHematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences.Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives.Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.Urinary elafin and kidney injury in hematopoietic cell transplant recipientsImpact of donor age on outcome after allogeneic hematopoietic cell transplantation.
P50
Q24630836-5940C582-0A53-4FA0-AC96-60359442FA1CQ24685958-9B34BBAA-A461-4CB2-9D6A-2722B34FEDC7Q26748780-5D94144E-C733-4BEE-B57A-42BEDDF92E1AQ30486842-2864CFC5-88C5-4A8C-BB0A-6F0A8FD68B7BQ30540989-3C26A543-BC67-4664-94C9-4386ECCC2207Q30543777-5D851FC1-104E-409C-A5EF-35E297CB4E06Q30558271-6E420B11-0DE0-430B-A5CF-662A0599CD66Q33348936-87DA7A5A-F86E-461C-B4B5-BBD4F0150D39Q33359498-8EB0EE01-019F-4520-98CB-EC47C614BC6EQ33388983-69308586-DDEB-4CD8-BF7E-68C38F33F8EDQ33396929-0DF857F0-BE61-4C71-9833-C5412E2C67DDQ33398529-BB02FDFD-6AC7-4D01-B343-1F90BC088B82Q33419003-8B806715-F35A-47C9-A476-D7CE149895FBQ33443876-A94BE11D-4C48-4F13-90A9-5F8562727454Q33560410-5895F534-62FD-46D7-AF2D-C439D620819FQ33653406-9E7608A7-4A96-4102-ABBA-2AE977BD941BQ33677489-6D653ADD-9B0D-4DC7-9BD5-ADA7EFD0C6E7Q33699602-576F7CC5-3015-4555-91AC-02D1A68975FDQ33771667-AEAA085F-F84C-4350-B436-3D436154CE84Q33905541-4B8A140A-ABE8-44BB-8202-52E226FDDD72Q33911314-2960F63F-BB3B-4D1C-A484-7527DC612BF8Q33925339-2780E571-54AD-438A-94E1-8EC942C5E7B7Q33958019-878BF555-E58A-40CE-92A9-F4B616027DCBQ33990856-6A09EFA5-624B-494F-B194-78837B1F2104Q34022682-39D7E96C-8453-4F67-81EA-921983125B23Q34106362-61BE28C2-C239-4E2F-AF6F-8C72668DC473Q34108254-E0B08780-EDCA-4216-8A8E-8C80432DEA06Q34175259-0D1500B7-A584-4F9D-9757-F7B683536421Q34186689-98993BFE-C790-49BC-8250-96A4E7BDE6E8Q34260505-1DC92E64-1D70-40AF-AB9C-8D83219A7C31Q34272554-5480072D-6A0F-48ED-8757-3196EA3745D1Q34370320-22873ACD-560E-4055-BCD6-FF8292822400Q34404171-5FB74E9C-6005-4A77-99B2-2027EDC9420BQ34472861-2D44A463-5405-4A7B-92F4-81DC095D86C7Q34543056-5B47119B-9A55-4F94-A915-9CAF825D9355Q34583041-51CFE319-B370-4B6D-8B93-6AB1EAE56841Q34630152-636429D6-6C67-43A3-8EB8-544DA7CA20EFQ34807259-87B4DD67-BFFF-426B-B715-06D7220F3F14Q34828433-4C738DBF-013A-4265-9F82-FC5F7352A6A5Q34859147-270A748E-AE8A-4DDB-8DE8-1909B251EDB3
P50
name
Brenda M Sandmaier
@en
Brenda M Sandmaier
@nl
type
label
Brenda M Sandmaier
@en
Brenda M Sandmaier
@nl
prefLabel
Brenda M Sandmaier
@en
Brenda M Sandmaier
@nl